SCHEMBL6342201

SCHEMBL6342201

CC(N)CCc1ccc2c(c1)CCO2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.43
CHRM1 P11229 2/20 0.43
CHRM3 P20309 2/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
PRKCI P41743 1/20 0.43
TAAR1 Q96RJ0 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
ACACB O00763 1/20 0.42
KCNH2 Q12809 2/20 0.42
ADRB2 P07550 1/20 0.42
CHRM4 P08173 1/20 0.42
ADRB1 P08588 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2A P08913 1/20 0.42
DRD2 P14416 1/20 0.42
KCNE1 P15382 1/20 0.42
ADRA2B P18089 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15218149 0.88 ACACB (0.43) CHRM2CHRM1CHRM3CHRNB2CHRNA4
SCHEMBL29804006 0.84 TAAR1 (0.59) PRKCITAAR1SLC6A4SLC6A2SLC6A3
SCHEMBL2561330 0.84 TAAR1 (0.59) PRKCITAAR1SLC6A4SLC6A2SLC6A3
SCHEMBL23862494 0.81 RAB9A (0.48) CHRM2CHRM1CHRM3PRKCISLC6A4
SCHEMBL2773998 0.79 TAAR1 (0.56) CHRM2CHRM1CHRM3CHRNB2CHRNA4
SCHEMBL1276487 0.79 RAB9A (0.46) CHRM2CHRM1CHRM3CHRNB2CHRNA4
SCHEMBL30079744 0.79 TAAR1 (0.45) PRKCITAAR1SLC6A4SLC6A2SLC6A3
SCHEMBL21893190 0.79 TAAR1 (0.45) PRKCITAAR1SLC6A4SLC6A2SLC6A3
Hydrochloric Acid SCHEMBL3714421 0.78 TAAR1 (0.54) CHRM2CHRM1CHRM3PRKCITAAR1
SCHEMBL5018746 0.78 ACACB (0.48) PRKCITAAR1ACACBKCNH2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849649-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. (US) 2005-02-01 US disclosed
US-20040106611-A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC 2004-06-03 US disclosed
EP-1373192-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD Pfizer Limited (GB) 2004-01-02 EP disclosed
US-6660756-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-12-09 US disclosed
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-06-05 US disclosed
WO-2002079143-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD PFIZER LIMITED (GB) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP CHRM2 1047/4885CHRM1 1265/4885CHRM3 630/4885
US-20040106611-A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP CHRM2 1300/4885CHRM1 1446/4885CHRM3 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.